Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis
Authors' conclusion
Decreasing production of bFGF, PlGF or IL-6 by 1-year tofacitinib therapy potentially inhibits synovial and aortic inflammation.
Study context
- Population
- RA patients undergoing 1-year tofacitinib therapy26 completed and analysed
- Participants
- 30 patients
- Outcome
- Angiogenic factors in relation to vascular inflammation and function, and clinical markers
- Follow-up
- 12 months
Methodological details12-month follow-up, single-group
- 12-month follow-up
- Single-group
Main finding
As reported in the abstract
Angiogenic biomarkers after 1-year tofacitinib
- Significant decrease in IL-6, VEGF, bFGF, EGF, PlGF and cathepsin K (CathK)
- P < 0.05
- Increase in Gal-3 production
- P < 0.05
Observational data: associations, not effects.
Further findings
Biomarkers by RF serostatus (subgroup)
- bFGF, PlGF and N-terminal prohormone brain natriuretic peptide (NT-proBNP) higher, PECAM-1 lower in RF-seropositive patients
- P < 0.05
Correlation with PET/CT synovial and aortic inflammation
- TNF-α, bFGF and PlGF correlated with post-treatment synovial inflammation; aortic inflammation dependent on IL-6 and PECAM-1
- P < 0.05
Correlation with common carotid intima-media thickness (ccIMT)
- NT-proBNP, CXCL8 and Cath variables correlated with ccIMT
- P < 0.05
Original publication
Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis. Rheumatology (Oxford). Published 23 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →